RxDoctor Payments Data

Gareth Weiner, MD

Gastroenterology · Thornton, CONPI 1003845249

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $292,698 of the $381,862 with a category attached, or 76.7%. 50 manufacturers reported payments, led by Sanofi at 28.1% of the total. Among gastroenterology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$381,862in general payments, 2019–2025

Across 1,245 payments — averaging $306.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$107K
  • Pfizer$74K
  • Regeneron Healthcare Solutions, Inc.$71K
  • AbbVie$42K
  • Takeda Pharmaceuticals U.S.A., Inc.$37K
  • E.r. Squibb & Sons, L.L.C.$32K
  • plus $18K from 44 others

What the payments were for

  • Consulting fees$16,0964%
  • Speaking & faculty fees$292,69877%
  • Travel & lodging$43,86411%
  • Food & beverage$28,8738%
  • Education$3200%
  • Gifts$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$381,862 in reported general payments places this provider in the 95th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$55,446
Medicare patients
274
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf75$12,486
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates179$11,879
LinzessLinaclotide11$8,854
ClenpiqSod Picosulf/Mag Ox/Citric Ac19$3,481
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag14$1,657
Pantoprazole Sodium126$1,475
Omeprazole75$810
Dicyclomine Hcl17$650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab, Suflave$680$14,14389 claims
AbbVieLinzess$41,835$8,85411 claims
Ferring Pharmaceuticals Inc.Clenpiq$166$3,48119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Thornton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →